Advertisement

Disclaimer information: LLS is not associated with any other content, and does not endorse any information, product, service, or advertisement, otherwise included within this site.

Issue 3

For the October 2021 Treating Blood Cancers healthcare professional podcast episode, Dr. Ken Miller sat down with Dr. Joshua Richter to discuss the physician's role in treating newly diagnosed patients. Here are some highlights.  Dr. Miller:  I've wondered as a community hematologist and oncologist when to start treatment. There are...

Assigning Risk Based on 17p Deletion in Multiple Myeloma – Not as Simple as...

Faith Davies, MBBCh, MD MRCP, MRCPath At first glance, it seems very simple: the presence of a deletion of the short arm of chromosome 17...

Targeting Dependence on the B-cell lymphoma 2 (Bcl-2) Family in Multiple Myeloma

Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD Department of Hematology and Medical Oncology, Emory University School of Medicine, and Winship Cancer Institute,...

T-Cell Redirecting Bispecific Antibodies for the Treatment of Multiple Myeloma

Niels W.C.J. van de Donk, MD, PhD Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands Introduction Multiple myeloma (MM) patients...

Issue 2

2021 ASCO Annual Meeting Urvi A. Shah, MD, Myeloma Service,  Memorial Sloan Kettering Cancer Center, New York As illustrated by the presentations at the 2021 ASCO annual meeting, the field of multiple myeloma (MM) is changing rapidly.1 However the jury is still out on whether we are curing a subset of...

MYELOMA 101 – PART II

Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Manisha Bhutani, MD, Charlotte, NC Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)...
COVID-19 Coronavirus Infections Viruses

COVID-19 AND MULTIPLE MYELOMA: VACCINATION, TREATMENT, AND MORE—YOUR QUESTIONS, ANSWERED

Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD March 11 marked the one-year anniversary of the World Health Organization declaring the COVID-19 outbreak a...

Championing Access to Care: Myeloma Link and Other Equity Focused Initiatives Run by the...

Elisa S. Weiss, PhD, Senior Vice President, Education, Services & Health Research, LLS, New York The Leukemia and Lymphoma Society (LLS) has a number of...

Biology and Therapy of Early Multiple Myeloma: Future Directions

Ola Landgren, MD, PhD, Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami Multiple myeloma (MM), the second most common hematologic malignancy, is consistently preceded...

26th Congress of the European Hematology Association/EHA 2021 Virtual Congress—Multiple Myeloma Highlights

María-Victoria Mateos, MD, PhD, Borja Puertas MD and Veronica González-Calle MD, PhD Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología...

Understanding the Patient’s Experience in Myeloma Care – a Conversation Between Myeloma Patients and...

Communication between the clinician and patient, as a two-way conversation, clarity on goals for treatment and treatment protocol, patient education, and support from other...

Issue 1

Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD March 11 marked the one-year anniversary of the World Health Organization declaring the COVID-19 outbreak a global pandemic. A year later, we are still learning the true impact of this pandemic on the delivery of cancer care globally. Clinical data on...

MYELOMA 101 – PART I

Incidence, disease presentation, and clinical diagnosis Based on the LLS Professional Education Webcast:Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management Orsi Giricz, PhD, and Saad...

AMERICAN SOCIETY OF HEMATOLOGY MEETING 2020 – MULTIPLE MYELOMA HIGHLIGHTS

Neha Korde, MD The year of 2020 marked a tumultuous period for the world of medicine, marred with a global pandemic that effectively gripped the...

MELFLUFEN: A TROJAN HORSE ALKYLATOR

Peter Voorhees, PhD The promise of the alkylating agent melphalan for the treatment of multiple myeloma (MM) was first documented in 1958 where reduction in...

HERE’S TO NEW BEGINNINGS!

Saad Z. Usmani, MD, MBA, FACP The COVID-19 pandemic brought on many challenges for our personal, professional, and communal lives. However, we witnessed an unprecedented...

HIGHLIGHTS FROM THE MARCH 2021 LLS PODCAST FOR HEALTHCARE PROFESSIONALS

Treating Blood Cancers: The LLS Podcast Series for Professionals provides up-to-date and accurate information on diagnosis, treatment, and survivorship considerations to educate healthcare professionals...

THE FIRST CAR T THERAPEUTIC FOR MULTIPLE MYELOMA – A CONVERSATION WITH DR. NIKHIL...

Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role in a...
- Advertisement -
- Advertisement -

Trending Stories

HIGHLIGHTS FROM THE LLS PODCAST, THE PHYSICIAN’S ROLE IN TREATING NEWLY DIAGNOSED PATIENTS

For the October 2021 Treating Blood Cancers healthcare professional podcast episode, Dr. Ken Miller sat down with Dr. Joshua Richter to discuss the physician's...

Assigning Risk Based on 17p Deletion in Multiple Myeloma – Not as Simple as...

Faith Davies, MBBCh, MD MRCP, MRCPath At first glance, it seems very simple: the presence of a deletion of the short arm of chromosome 17...

Targeting Dependence on the B-cell lymphoma 2 (Bcl-2) Family in Multiple Myeloma

Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD Department of Hematology and Medical Oncology, Emory University School of Medicine, and Winship Cancer Institute,...

T-Cell Redirecting Bispecific Antibodies for the Treatment of Multiple Myeloma

Niels W.C.J. van de Donk, MD, PhD Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands Introduction Multiple myeloma (MM) patients...

Recent Advances in Myeloma Show Promising Results – Are We Curing Patients or Kicking...

2021 ASCO Annual Meeting Urvi A. Shah, MD, Myeloma Service,  Memorial Sloan Kettering Cancer Center, New York As illustrated by the presentations at the 2021 ASCO...

MYELOMA 101 – PART II

Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Manisha Bhutani, MD, Charlotte, NC Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)...